are methylphenidate, modafinil and armodafinil all stimulants used for adhd?

“rolin, modafanyl, arm modafanyl, all these things are stimulants.”

a host, a neuroscientist said on Huberman Lab, 2026-10-01, at 34:24. hear it in context →

first, the part that holds

The speaker is right that all three are treated as stimulants in the federal record. Methylphenidate's label calls it a central nervous system stimulant. The drug enforcement agency's rule scheduling modafinil calls it "a central nervous system (CNS) stimulant", and that rule covers its isomers, which includes armodafinil.

what we found when we went and looked

We read the FDA labels for all three drugs, the drug enforcement agency's current controlled-substance list and its 1999 scheduling rule. Methylphenidate is labeled a central nervous system stimulant (Schedule II, code 1724). Modafinil is Schedule IV (code 1680), and the rule that scheduled it calls it a CNS stimulant. The modafinil and armodafinil labels use a different term, "wakefulness-promoting agent", and say the drugs' "pharmacologic profile is not identical to that of the sympathomimetic amines." The ADHD part of the claim is where it overreaches. Methylphenidate is FDA-approved for ADHD. The modafinil label says it "is not approved for use in pediatric patients for any indication". A 133-trial network meta-analysis found modafinil beat placebo in children but not in adults.

assertion by assertion

both directions

for the speaker: The federal scheduling record calls modafinil a CNS stimulant, and the same rule covers armodafinil because it is an isomer. Both FDA labels say modafinil and armodafinil have wake-promoting actions similar to sympathomimetic agents including amphetamine and methylphenidate, and that they bind the dopamine transporter and block dopamine reuptake. Modafinil's label says it produces euphoric effects typical of other CNS stimulants, monkeys trained on cocaine self-administer it, and in people with a history of drug use its effects were consistent with methylphenidate. Modafinil also showed real effects on ADHD symptoms in children in randomized trials.

against: The FDA labels never call modafinil or armodafinil a stimulant in their own description. They use "wakefulness-promoting agent" and note that the pharmacologic profile differs. The labels also give lab evidence: unlike amphetamine, modafinil's wake-promoting effect was not blocked by the dopamine blocker haloperidol in rats, and a dopamine-synthesis blocker did not stop its effect on movement. The schedule tiers differ too: methylphenidate is Schedule II, modafinil Schedule IV. That puts them at different levels of regulatory concern, which "all these things are stimulants" flattens. On ADHD, neither modafinil nor armodafinil is approved, modafinil is not approved for anyone under 17, and the meta-analysis found no benefit over placebo in adults.

what this cannot say

The quote itself only says the drugs are stimulants. The ADHD part comes from the claim sentence we were given, so we graded the stimulant point as the headline. We could not read the current 21 CFR 1308.14 text directly because the site redirected us. Our scheduling evidence is the 1999 rule and the drug enforcement agency's August 2026 list, which shows modafinil in Schedule IV but does not name armodafinil separately. The armodafinil label we read is a 2010 version, the modafinil label is from 2015, and the methylphenidate document is a 2013 medication guide for one product. Later revisions may word things differently. We did not read the 2006 FDA advisory committee record on modafinil for pediatric ADHD, so we do not cite it. The meta-analysis covers short-term trials only and does not include armodafinil. How often prescribers use either drug off-label for ADHD is not something these sources can answer.

sources, each one fetched and read

1. US FDA, modafinil tablets prescribing information, NDA 020717, revised 01/2015, accessdata.fda.gov What we read there: Indicated "to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD)." Rash leading to discontinuation in about 0.8% (13 per 1,585) of pediatric patients; "not approved for use in pediatric patients for any indication"; "a Schedule IV controlled substance"; a "wakefulness-promoting agent" whose effects are "typical of other CNS stimulants" and whose "pharmacologic profile is not identical to that of the sympathomimetic amines." Fetched 2026-10-06 (HTTP 200). https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020717s037s038lbl.pdf
2. US FDA, armodafinil tablets prescribing information, NDA 021875, October 2010, accessdata.fda.gov What we read there: Marked [C-IV]. Armodafinil "is a wakefulness-promoting agent" and "the R-enantiomer of modafinil". It "is not a direct- or indirect-acting dopamine receptor agonist" but binds the dopamine transporter; it has "wake-promoting actions similar to sympathomimetic agents including amphetamine and methylphenidate, although their pharmacologic profile is not identical." Effectiveness established in obstructive sleep apnea, narcolepsy and shift work disorder. Fetched 2026-10-06 (HTTP 200). https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021875s005s008s015lbl.pdf
3. US FDA, methylphenidate hydrochloride sustained-release labeling and medication guide, NDA 010187, 2013, accessdata.fda.gov What we read there: "a central nervous system stimulant prescription medicine" used "for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD)" and narcolepsy; "a federally controlled substance (CII) because it can be abused or lead to dependence." Fetched 2026-10-06 (HTTP 200). https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/010187s077lbl.pdf
4. US Drug Enforcement Administration, Diversion Control Division, Controlled Substances - Alphabetical Order, dated 27-Aug-26 What we read there: Methylphenidate: code 1724, Schedule II, non-narcotic. Modafinil: code 1680, Schedule IV, non-narcotic. Fetched 2026-10-06 (HTTP 200). https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf
5. US Drug Enforcement Administration, final rule placing modafinil in Schedule IV, Federal Register vol. 64 no. 17, 27 January 1999, govinfo.gov What we read there: Places "modafinil, including its salts, isomers and salts of isomers, into Schedule IV"; "Modafinil is a central nervous system (CNS) stimulant that produces many of the same pharmacological effects and adverse reactions as classic psychomotor stimulants, but at higher doses"; its mechanism "is not clearly defined." Fetched 2026-10-06 (HTTP 200). https://www.govinfo.gov/content/pkg/FR-1999-01-27/html/99-1791.htm
6. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis, Lancet Psychiatry, 2018;5(9):727-738, PMC6109107 What we read there: 133 double-blind RCTs (10,068 children and adolescents, 8,131 adults in efficacy analyses). Clinician-rated vs placebo: in children and adolescents, modafinil SMD -0.76 (-1.15 to -0.37) and methylphenidate -0.78 (-0.93 to -0.62); in adults, methylphenidate -0.49 (-0.64 to -0.35) beat placebo but modafinil 0.16 (-0.28 to 0.59) did not. Supports "methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications." Fetched 2026-10-06 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC6109107/

speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam